Day: June 1, 2020

Tuusulan asuntomessuilla esiteltävä Honka Huomen -hirsitalo suunniteltiin kaikille aisteilleMEDIATIEDOTE 1.6.2020 klo 10.00Hirsirakentamisen edelläkävijä Honkarakenne Oyj esittelee Tuusulan asuntomessuilla 2020 Honka Huomen -konseptitalon (kohde 41), joka aktiivisesti lisää asukkaidensa hyvinvointia. Honka Huomen -talossa terveelliset luonnonmateriaalit ja ekologinen hirsirakentaminen yhdistyvät asumisen laatua parantavaan älykkääseen talotekniikkaan ja kaikkia aisteja inspiroivaan taiteeseen! Talo tulee myyntiin kesällä 2020.Honka Huomen -talomallisto suunniteltiin erityisesti kaupunkien pienille tonteille sopivaksi. Kompaktin L-muotoisen talon syliin jää oma pieni piha, jota suojaavat piharakennukset. Oleskelutilassa suuret lasiseinät kutsuvat ympäröivän maiseman sisään. Sisäpihan suuret lasiseinät kutsuvat ympäröivän maiseman sisään....

First-in-class TIM-based non-gene edited allogeneic CAR-T candidate, CYAD-101, shows encouraging clinical activity with no evidence of graft-versus-host disease in relapsed/refractory metastatic colorectal cancer patientsTwo patients achieved a confirmed partial response and nine patients achieved stable disease, leading to a disease control rate of 73%Overall safety and clinical activity data are HLA-independent indicating that CYAD-101 cells can be used in a broad patient population regardless of the HLA haplotypeExpansion cohort of the alloSHRINK trial evaluating CYAD-101 following FOLFIRI preconditioning chemotherapy is expected to begin in the fourth quarter 2020shRNA platform for next-generation allogeneic CAR-T candidates provides proof-of-principle to simultaneously knockdown up to four genes in a single constructManagement to...

Not for release, publication or distribution, in whole or in part, in or into or from US, Japan, Australia or any other jurisdiction where to do so would constitute a violation of the relevant laws or regulations of such jurisdiction.ABN AMRO announces call of EUR 1.5bn Tier 2 instrument (XS1253955469)With reference to the Terms and Conditions of the EUR 1.5 billion Subordinated Fixed-to-Fixed Rate Notes due June 2025 callable on Year 5 under the Programme for the issuance of Medium Term Notes of ABN AMRO Bank N.V. with ISIN XS1253955469 ABN AMRO Bank N.V. announces to exercise its right to redeem these Notes in full on 30 June 2020. Trading will be suspended as of 26 June 2020.This press release shall not constitute an offer to purchase or the solicitation of an offer to purchase, nor shall there be any offer or sale of these Subordinated...

Dit bericht mag geheel noch gedeeltelijk worden vrijgegeven, gepubliceerd of verspreid in, naar of vanuit de Verenigde Staten, Japan, Australië of enige andere jurisdictie waar dit zou worden aangemerkt als een overtreding van de aldaar geldende wet- of regelgeving.  ABN AMRO kondigt aflossing aan van Tier 2-instrument van EUR 1,5 miljard (XS1253955469)Onder verwijzing naar de voorwaarden van de Subordinated Fixed-to-Fixed Rate Notes (ISIN XS1253955469) met een omvang van EUR 1,5 miljard en een looptijd tot juni 2025, die in het vijfde jaar aflosbaar zijn onder het Programme for the issuance of Medium Term Notes van ABN AMRO Bank N.V., kondigt ABN AMRO Bank N.V. aan dat zij haar recht uitoefent om deze Notes volledig af te lossen op 30 juni 2020. De handel in deze Notes wordt op 26 juni 2020 beëindigd.Dit persbericht geldt noch als een...

This announcement contains inside information for the purposes of Article 7 of the Market Abuse Regulation (EU) No 596/2014.Cambridge, UK and Indianapolis, US –  1 June 2020: Acacia Pharma Group plc (“Acacia Pharma”, the “Group” or the “Company”) (EURONEXT: ACPH), a commercial-stage biopharmaceutical company focused on developing and commercializing novel products to improve the care of patients undergoing serious medical treatments such as surgery, invasive procedures or chemotherapy, announces an amendment to the terms of its loan agreement with a wholly-owned subsidiary of Cosmo Pharmaceuticals N.V. (“Cosmo”).Under the terms of the amendment, the €10 million loan facility that was made available on the approval of BARHEMSYS® is terminated and replaced with a €10 million equity investment at a price of €3.112 per share, which represents...

VALMIERAS STIKLA ŠĶIEDRA, AS publishes its management report and the unaudited financial statements for the first three months of 2020, which can be seen in the attachment below in two languages: in Latvian and in English.VALMIERAS STIKLA ŠĶIEDRA, AS and its subsidiaries (hereinafter – VALMIERA GLASS GROUP) is one of the leading glass fibre manufacturers in Europe, with more than 55 years of experience in fiberglass production. VALMIERA GLASS GROUP’s core business areas are glass fibre research, glass fibre product development, production and trade. VALMIERA GLASS GROUP is the only group in the world with a vertically integrated structure and a wide range of glass fibre products for the thermal insulation market with a temperature resistance up to 1250°C.Contact information:VALMIERAS STIKLA ŠĶIEDRA, ASPhone: +371 64202216E-mail:...

AS VALMIERAS STIKLA ŠĶIEDRA publicē uzņēmuma vadības ziņojumu un neauditēto konsolidēto finanšu informāciju par 2020. gada pirmajiem trīs mēnešiem, ar kuru var iepazīties pielikumā zemāk divās valodās: latviešu un angļu valodā.AS VALMIERAS STIKLA ŠĶIEDRA un tās meitas uzņēmumi (turpmāk tekstā saukta – VALMIERA GLASS GRUPA) ir viens no vadošajiem stikla šķiedras ražotājiem Eiropā ar vairāk nekā 55 gadu pieredzi stikla šķiedras ražošanā. VALMIERA GLASS GRUPAS pamatdarbības virzieni ir stikla šķiedras pētniecība, stikla šķiedras produktu izstrāde, ražošana un pārdošana. VALMIERA GLASS GRUPA ir vienīgā uzņēmumu grupa pasaulē ar vertikāli integrētu struktūru un plašu stikla šķiedras produktu klāstu termoizolācijas tirgum ar temperatūras noturību līdz pat 1250°C.Kontaktinformācija:AS VALMIERAS STIKLA ŠĶIEDRATel.: +371 64202216E-pasts: latv...

MACAU, June 01, 2020 (GLOBE NEWSWIRE) — Melco Resorts & Entertainment announces the publication of its 2019 sustainability report (link). Since launching the Company’s Above and Beyond sustainability strategy, the report highlights the positive and substantial progress made towards the Company’s sustainability goals, including inspiring the Company’s resort guests by showing them that a sustainable future is a better future; being the best partner and the best place to work; achieving carbon neutrality across all resort properties; and achieving zero waste and contributing to circular economic leadership in Asia by the year 2030.Mr. Lawrence Ho, Chairman & CEO of Melco Resorts & Entertainment, said, “Last year, Melco’s inaugural Above & Beyond sustainability strategy set out a comprehensive series of bold, strategic...

SHANGHAI, China, May 31, 2020 (GLOBE NEWSWIRE) — Hua Medicine (the “Company”, Stock Code: 2552. HK), a leading innovative drug development company focused on developing novel therapies for the treatment of diabetes, is pleased to announce that the Company has been officially included as a constituent stock of the MSCI Hong Kong Micro Cap Index. The relevant change has been implemented as of the close of May 29, 2020.MSCI is a leading provider of research-based indexes and analytics worldwide. The indices cover thousands of securities from different geographic sub-areas and cap sizes that have good operational results and potential. The MSCI market cap weighted indices are amongst the most respected and widely used benchmarks in the financial industry, and the Hong Kong Micro Cap Index is widely used among institutional investors....

上海, June 01, 2020 (GLOBE NEWSWIRE) — 華領醫藥（「公司」，香港聯交所股份代號：2552.HK），一家針對糖尿病臨床需求開發全球首創新藥的研發公司，欣然公佈公司已被正式納入MSCI香港微型股指數，相關指數調整已於2020年5月29日收市後生效。MSCI是環球領先的基於研究的指數和分析提供商，其指數囊括數以千計的來自不同地區和不同市值並且具有良好營運業績和發展潛力的股票。MSCI市值加權指數體系是金融行業之中最受尊重和廣泛使用的基準之一，並且MSCI香港微型指數廣為機構投資者所採用。成為MSCI香港微型指數的成分股之一是華領醫藥的榮譽，這將增強公司在投資者中的信譽，是對公司作為中國領先的生物科技企業所取得的成就的認可，是具有重要意義的里程碑事件。華領醫藥的發展目標是成為一家全球性的糖尿病治療和管理公司，上市以來取得了眾多核心業務的進展。全球首創新藥雙重機制葡萄糖激酶啟動劑dorzagliatin的單藥治療III期臨床研究（HMM0301）已達到24周主要療效終點，公司的dorzagliatin產品組合持續擴大，近期公佈的臨床研究資料，不斷夯實dorzagliatin作為糖尿病基石藥物的基礎，通過單藥或是聯合諸多現有口服抗糖尿病藥物，如二甲雙胍、恩格列淨（一種SGLT-2抑制劑）和西格列汀（一種DPP-4抑制劑）等，具有控制糖尿病進展、抑制或延遲併發症發生的巨大前景。公司計畫於2020年第三季度結束前公佈HMM0301的頂線52周核心資料結果。另一項dorzagliatin聯合二甲雙胍的聯合用藥III期臨床試驗HMM0302已完成24周患者訪視，公司計畫於2020年第三季度結束前公佈HMM0302的頂線24周核心資料結果，以及在2020年年底前公佈頂線52周核心資料結果。華領醫藥CEO陳力博士表示：“我們將繼續為建立糖尿病治療新標準而不斷努力，深入推進dorzagliatin+發展戰略，建設創新、共用、共贏的血糖穩態科學平臺，秉承「患者為先、創新為本、良藥為民」的宗旨，持續為dorzagliatin及相關產品在中國乃至全世界範圍內的研發、註冊和上市做出努力，以更出色的業務表現回饋廣大的投資者並造福全球糖尿病患者。”關於Dorzagliatin   ...